The results revealed that high expression of MYC, MMP14, TNFAIP6, and PTGER4 were correlated with drug sensitivity of cancer cells to a multitude of chemotherapeutic drugs, especially MYC, which was highly correlated with Palbociclib, Carmustine, Ifosfamide, Parthenolide, etc. Conversely, increased expression of MMP14, RIPK2, LDLR, and PTGER4 was associated with increased drug resistance of cancer cells to Oxaliplatin, Lomustine, Decitabine, Dexrazoxane, trametinib, etc. (Figure 9). Here, RIPK2 is linked to cancer.